BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 18028436)

  • 41. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
    Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
    Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
    Pancewicz SA; Izycka A; Klibingat M; Zajkowska JM; Swierzbińska-Pijanowska R; Kondrusik M; Grygorczuk SS; Izycki T; Hermanowska-Szpakowicz T
    Pol Merkur Lekarski; 2008 Dec; 25(150):495-9. PubMed ID: 19205380
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Matrix metalloproteinase (MMP)-2 genetic variants modify the circulating MMP-2 levels in end-stage kidney disease.
    Marson BP; Lacchini R; Belo V; Dickel S; da Costa BP; Poli de Figueiredo CE; Tanus-Santos JE
    Am J Nephrol; 2012; 35(3):209-15. PubMed ID: 22302011
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in premenopausal obese women: relationship to cardiac function.
    Kosmala W; Plaksej R; Przewlocka-Kosmala M; Kuliczkowska-Plaksej J; Bednarek-Tupikowska G; Mazurek W
    Int J Obes (Lond); 2008 May; 32(5):763-71. PubMed ID: 18197181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. In-hospital outcome of patients with acute coronary syndrome: relationship with inflammation and remodeling markers.
    Giansante C; Fiotti N; Di Chiara A; Altamura N; Wasserman S; Fioretti P; Guarnieri G
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):602-7. PubMed ID: 17667031
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood.
    Mannello F; Jung K; Tonti GA; Canestrari F
    Clin Biochem; 2008 Dec; 41(18):1466-73. PubMed ID: 18926810
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing-remitting multiple sclerosis treated with interferon beta.
    Boz C; Ozmenoglu M; Velioglu S; Kilinc K; Orem A; Alioglu Z; Altunayoglu V
    Clin Neurol Neurosurg; 2006 Feb; 108(2):124-8. PubMed ID: 16412833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Matrix metalloproteinase-1 and its inhibitor, TIMP-1, in systolic heart failure: relation to functional data and prognosis.
    Jordán A; Roldán V; García M; Monmeneu J; de Burgos FG; Lip GY; Marín F
    J Intern Med; 2007 Sep; 262(3):385-92. PubMed ID: 17697160
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Systemic regulation of angiogenesis and matrix degradation in bone regeneration--distraction osteogenesis compared to rigid fracture healing.
    Weiss S; Zimmermann G; Baumgart R; Kasten P; Bidlingmaier M; Henle P
    Bone; 2005 Dec; 37(6):781-90. PubMed ID: 16202678
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
    Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
    Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Matrix metalloproteinase-9 and matrix metalloproteinase-2 as biomarkers of various courses in multiple sclerosis.
    Benesová Y; Vasku A; Novotná H; Litzman J; Stourac P; Beránek M; Kadanka Z; Bednarík J
    Mult Scler; 2009 Mar; 15(3):316-22. PubMed ID: 19153173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
    Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
    Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in tissues with a diagnosis of childhood lymphoma.
    Bozkurt C; Ertem U; Oksal A; Sahin G; Yüksek N; Birgen D
    Pediatr Hematol Oncol; 2008 Sep; 25(7):621-9. PubMed ID: 18850474
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension.
    Derosa G; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo S; Montagna L; Gravina A; Ferrari I; Galli S; Paniga S; Tinelli C; Cicero AF
    Endothelium; 2006; 13(3):227-31. PubMed ID: 16840178
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer.
    Rauvala M; Turpeenniemi-Hujanen T; Puistola U
    Anticancer Res; 2006; 26(6C):4779-84. PubMed ID: 17214341
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The expression of human corneal MMP-2, MMP-9, proMMP-13 and TIMP-1 in bullous keratopathy and keratoconus.
    Predović J; Balog T; Marotti T; Gabrić N; Bohac M; Romac I; Dekaris I
    Coll Antropol; 2008 Oct; 32 Suppl 2():15-9. PubMed ID: 19138000
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Balance between matrix metalloproteinases (MMP) and tissue inhibitors of metalloproteinases (TIMP) in the cervical mucus plug estimated by determination of free non-complexed TIMP.
    Becher N; Hein M; Uldbjerg N; Danielsen CC
    Reprod Biol Endocrinol; 2008 Sep; 6():45. PubMed ID: 18826601
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
    Swellam M; Arab LR; Bushnak HA
    IUBMB Life; 2007 Jun; 59(6):394-401. PubMed ID: 17613170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.